MARKETS / NASDAQ / PSTV
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Plus Therapeutics, Inc. PSTV

17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.2M
▼ 10.5% vs FY2024
EPS · FY25
$-0.29
Dividend / sh · FY25
Payout · FY25
ROE · FY25
Net margin · FY25
-429.4%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.2M
Revenue, FY2025 · full 17-year series below
Revenue Net income
0.00250.0050.00750.010.0-0.02009201220152018202120242025
0.00250.0050.00750.010.0-0.02016201920222025

The company lost 429 cents on every revenue dollar this year.

Per share
USD -0.29
Diluted EPS, FY2025
EPS
0.40.81.2-0.292009201220152018202120242025
0.40.81.2-0.292016201920222025

The company pays no cash dividend.

Profitability
Return on equity, FY2025
ROE
0.250.50.7512009201220152018202120242025
0.250.50.7512016201920222025
Operating margin-293.5%
Net margin-429.4%
Return on assets-195.0%

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.7%
−3.0%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.14B
Shares outstanding, FY2025
0.050.142009201220152018202120242025
0.020.142016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 16.3M
total assets, end of FY2025
Total assetsUSD 16.3M
EquityUSD 4.0M
CashUSD 4.3M
Current ratio1.23×

Equity funds 24% of total assets.

History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.29
−2.34
−4.24
−11.58
−1.11
−1.86
−8.27
−86.98
−8.23
−1.28
−2.07
−0.48
−0.39
−0.55
−0.61
−0.60
−0.65
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−522.5
−234.7
−193.3
−393.3
−341.0
−138.6
−189.2
−190.1
−576.4
·
−546.1
−393.6
−197.8
−286.2
·
Shares out B
0.14
0.01
0.00
0.00
0.02
0.01
0.00
0.00
0.01
0.02
0.01
0.10
0.07
0.07
0.06
0.05
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed